{"id":"escitalopram-venlafaxine-lithium","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Insomnia"},{"rate":"15-25","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Tremor (lithium-related)"},{"rate":"10-20","effect":"Polyuria/polydipsia (lithium-related)"},{"rate":"10-15","effect":"Weight gain"},{"rate":"10-15","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram selectively inhibits serotonin reuptake, while venlafaxine inhibits both serotonin and norepinephrine reuptake, together increasing synaptic availability of these neurotransmitters. Lithium acts as a mood stabilizer through multiple mechanisms including modulation of intracellular signaling pathways and neuroprotection. This polypharmacy approach is used to treat treatment-resistant depression and bipolar disorder.","oneSentence":"This is a combination therapy using escitalopram (SSRI) and venlafaxine (SNRI) to enhance serotonin and norepinephrine reuptake inhibition, with lithium added for mood stabilization and augmentation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:45:44.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"},{"name":"Bipolar disorder (depression phase)"},{"name":"Major depressive disorder with augmentation"}]},"trialDetails":[{"nctId":"NCT05603104","phase":"PHASE3","title":"Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-04-27","conditions":"Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression","enrollment":1254},{"nctId":"NCT05973786","phase":"PHASE3","title":"The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.","status":"RECRUITING","sponsor":"Dr. Inge Winter","startDate":"2025-02-11","conditions":"Bipolar Depression","enrollment":418},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT00080158","phase":"PHASE2, PHASE3","title":"Treatment of Adolescent Suicide Attempters (TASA)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2004-03","conditions":"Depression, Suicide, Attempted","enrollment":120},{"nctId":"NCT02441387","phase":"","title":"Predictors of the Outcome of Late Life Depression","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-04","conditions":"Major Depression","enrollment":120},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":"Depression","enrollment":104},{"nctId":"NCT00974155","phase":"PHASE4","title":"The Early Medication Change (EMC) Trial","status":"COMPLETED","sponsor":"K. Lieb","startDate":"2009-09","conditions":"Depression","enrollment":889},{"nctId":"NCT01896349","phase":"NA","title":"Interpersonal Psychotherapy for Treatment Resistant Depression","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2013-04","conditions":"Treatment Resistant Depression","enrollment":74},{"nctId":"NCT00612807","phase":"PHASE1, PHASE2","title":"Treatment of Mood and Marriage Study (TOMMS)","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-07","conditions":"Major Depressive Disorder, Partner Relational Disorder (V61.10)","enrollment":42},{"nctId":"NCT00704860","phase":"PHASE4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","startDate":"2005-02","conditions":"Major Depression","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Escitalopram, venlafaxine, lithium","genericName":"Escitalopram, venlafaxine, lithium","companyName":"K. Lieb","companyId":"k-lieb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination therapy using escitalopram (SSRI) and venlafaxine (SNRI) to enhance serotonin and norepinephrine reuptake inhibition, with lithium added for mood stabilization and augmentation. Used for Treatment-resistant depression, Bipolar disorder (depression phase), Major depressive disorder with augmentation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}